and meta-analysis

SYSTEMATIC REVIEW

Epidemiology of arboviruses in humans and livestock in Ethiopia: a systematic review

Alemu Gedefie^{1*}, Habtu Debash¹, Altaseb Beyene Kassaw², Gossa Mankelkl², Yeshi Metaferia¹, Melaku Ashagrie Belete¹, Sisay Desale¹, Saleamlak Sebsibe¹, Mihret Tilahun¹, Bruktawit Eshetu¹, Agumas Shibabaw¹, Yeshimebet Kassa¹, Hussen Ebrahim¹, Zewudu Mulatie¹, Ermiyas Alemayehu¹, Lebasie Woretaw³, Berhanu Kebede⁴, Minwuyelet Maru Temesgen⁵, Natan Kassaye Msganew⁶ and Melkam Tesfaye¹

Abstract

Background Arbovirus infections are a global public health threat, accounting for approximately 73% of the total emerging and re-emerging human infections, where the burden is worsened in sub-Saharan Africa, including Ethiopia. However, the surveillance system has been still challenged, and their burden and magnitude are not well estimated due to underestimates of true arbovirus burdens by passive case detections. To support targeted evidence-based public health decision-making, comprehensive evidence of arbovirus prevalence is crucial. Thus, the aim of this study was to assess the prevalence of arboviruses in humans and livestock in Ethiopia.

Method Articles were extensively searched in bibliographic databases and gray literatures using entry terms or phrases. PRISMA 2020 flow diagram was used and data among studies meeting eligibility criteria extracted in MS Excel sheet and exported into STATA-17 software for analysis. A random-effects model was used to compute the pooled magnitude of arboviruses in humans and livestock. The heterogeneity was quantified using the l² value. Publication bias was assessed using a funnel plot and Egger's test. Sensitivity analysis, subgroup analysis and meta-regression were performed to explore heterogeneity.

Result Of the 1957 studies identified, 39 human and 6 livestock studies were eligible for meta-analysis. The overall pooled sero-epidemiology of arboviruses in humans using anti-IgG and anti-IgM was 15.43% (95% CI: 12.11-18.76) and 10.04% (95% CI: 6.46-13.62), respectively. The molecular prevalence of arboviruses in humans was 38.42% (95% CI: 21.77-55.08). The pooled prevalence of arboviruses in livestock was 15.77% (95% CI: 0.45, 31.08). Dengue virus, Yellow fever virus, Zika virus, Rift valley fever, West Nile virus, and chikungunya virus in humans and Rift valley fever, West Nile virus, and Schmallenberg virus in livestock were reported.

Conclusion The magnitude of arboviruses in humans and livestock in Ethiopia alarms the need for immediate multi-sectoral interventions such as strengthening laboratory diagnostic capacities, undertaking an integrated regular national surveillance, and implementation of one-health initiatives and a planetary health approach.

Keywords Arboviruses, Ethiopia, Human, Livestock, Systematic review and meta-analysis

*Correspondence: Alemu Gedefie alemugedefie@gmail.com Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.



Background

Globally, arbovirus infect millions of individuals and pose a significant emerging and re-emerging public health threats. These viruses account for approximately 73% of all newly identified human infections [1]. Arboviral diseases affect over half of the world's population, resulting hundreds of millions of cases annually. For instance, the dengue virus alone is responsible for more than 390 million infections each year [2], while yellow fever caused 84,000-170,000 severe cases and 29,000-60,000 deaths in Africa in 2013 [1]. The global economic burden is estimated at \$8-9 billion per year, encompassing costs related to illness and vector control. This burden is expected to increase as climate change affects transmission dynamics [3]. The cumulative reported cost of arboviral diseases was estimated to be \$87.3 billion from 1975 to 2020 [4] and the costs of vector control programs was ranged from 5.62 to 73.5 million USD [5].

The predominant arboviruses co-circulating in the African region includes Yellow fever virus (YFV), dengue virus (DENV), Chikungunya virus (CHIKV), Rift Valley fever (RVF), West Nile virus (WNV), and Zika virus (ZIKV) [6]. In sub-Saharan Africa (SSA), these arboviral diseases impose enormous health and economic burdens, leading to increased mortality, morbidity, and disability in the region [7, 8]. Thus, there is an urgent need to strengthen epidemiological characterization and enhance control capabilities [7, 8].

Global trends such as climate change, population growth, and human activities like increased travel and trade connectivity, are facilitating the geographic expansion and evolution of arboviruses, altering vector life cycles and viral transmission dynamics, which heightens the risk of disease outbreaks [1, 9, 10]. On the contrary, surveillance systems continue to face significant challenges due to different factors. Passive case detection often underestimates the true arbovirus burdens due to the non-specific clinical presentations of DENV, CHIKV, and ZIKV [2]. Additionally, limited diagnostic capacities in resource limited countries hinder effective epidemiological analyses and response monitoring [11]. The lack of viability for confirmatory testing of surveillance samples [12] as well as integrated vector surveillance, is rarely sustained, yet critical for outbreak preparedness.

Moreover, these infections are associated with loss of productivity and increased healthcare costs as a result of prolonged illness and disability from infections. Emerging outbreaks might occur due to the invasion of naïve populations by Chikungunya's, which leads to escalating demand for services [13]. The problem is also certainly higher in rural communities where farming and livestock are carried out. In forested areas, the risk of yellow fever is higher, particularly in immunologically naive travelers and workers. However, knowledge of circulating virus strains involved in transmission remains limited in highrisk areas of the African region.

Despite the substantial burden of arboviral diseases in SSA, critical gaps remain in generating comprehensive evidence necessary for targeted public health decision-making. Although some initiatives have improved certain research aspects, the lack of integrated, multidisciplinary investigations hampers our understanding of the dynamic relationships driving local transmission [14]. Furthermore, up-dated and comprehensive evidence is needed for outbreak preparedness; however, comprehensive data of cocirculating strains of arboviruses in Ethiopia is lacking. This review aims to address this gap by enhancing our understanding of arbovirus epidemiology in Ethiopia, providing a foundation for evidencebased decision-making in integrated disease prevention and control from human and animal health dimensions. Therefore, the aim of this systematic review and metaanalysis (SRMA) is to determine the overall pooled magnitude of arboviruses among humans and livestock in Ethiopia.

Methods

Protocol registration and guidelines

This SRMA was developed and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA) [15] as indicated in Supplementary File 1. The protocol for this review was originally registered in the International Prospective Register of Systematic Reviews (PROSPERO) database with registration identification number CRD42024561271, available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024561271.

Data source, search strategy and selection of studies

A systematic and comprehensive search of the existing literature was carried out using multiple electronic databases, including PubMed/Medline, Epistimonikos, and Embase. Additionally, grey literature such as Wiley Online Library, Science Direct, Research Gate, African Journal Online (AJOL), Google Scholar, and Web of Sciences were used to retrieve potentially eligible studies reporting the prevalence of the common arboviruses (Dengue virus, Yellow fever virus, West Nile virus, Zika virus, Chikungunya virus, Rift valley fever, and Schmallenberg virus) among humans and livestock in Ethiopia. In order to include additional relevant studies omitted during electronic database searches, a snowball search was conducted using the bibliographies of the identified studies. Generally, the search was conducted from April 20, 2024, to May 20, 2024.

An extensive comprehensive search strategy was employed using the condition, context, population, and outcome of interest (CoCoPop) framework to formulate research questions [16]. The research question was formulated as "What is the prevalence of arboviral infections in humans and livestock's' of Ethiopia?". Moreover, the CoCoPop framework was condition (arboviral infections), context (Ethiopia), and population (humans and livestock's). To access all eligible studies, Medical Subject Headings (MeSH) terms and combination key words including "prevalence", "outbreak", "sero-prevalence", "Sero-positivity", "detection", "epidemiology", "burden", "magnitude", "Arbovirus", "Dengue virus", "Zika virus", "West Nile Virus", Yellow fever virus", "Chikungunya virus", "Chikungunya fever", "Schmallenberg virus", "YFV", "DENV", "RVF", "ZIKV", "CHIKV", "SBV", and "Ethiopia" were employed. Boolean operators such as "OR" and "AND" were used as necessary in the advanced search databases. Furthermore, the bibliographies of included studies were reviewed for additional articles, and authors were contacted to obtain any missing papers. Duplicates were removed after the search results were organized using Endnote 20 software (Clarivate Analytics USA). Three independent reviewers (AG, MAB, and EA) identified the articles from databases and other sources and removed duplicates. Subsequently, two independent reviewers (HD, LW) screened the titles and abstracts of all retrieved studies, cross-checked by a third reviewer (MT), followed by assessment of the full texts of potentially eligible studies against inclusion criteria by two reviewers (AS and MT), verified by a third reviewer (HE), and added to the extraction collection. Disagreements during each screening stage were resolved through consensus between the two reviewers and/or intervention of a third reviewer (MT).

Eligibility criteria

All articles published in peer-reviewed journals or grey literature in English language and reporting the prevalence of arbovirus infection and/or its genetic variants were included in this SRMA. Moreover, all laboratorybased observational studies, including cross-sectional studies, case-control, and cohort studies using laboratory detection methods such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assays (ELISA) for detecting arboviruses such as RNA, IgG, IgM, Non-structural protein-1 and plaque reduction neutralization tests (PRNT) from clinical specimens and livestock in Ethiopia until April 30, 2024, were included. However, reviews, qualitative studies, author replies, letters to the editor, case reports and commentaries were excluded from this SRMA.

Risk of bias assessment

The quality of studies included in this SRMA was evaluated by three authors (ZM, MAB and BK) using the Joanna Briggs Institute (JBI) quality appraisal tool designed for prevalence studies [17]. The critical appraisal checklist was used to evaluate the methodological quality of studies included in the SRMA. Finally, studies with an average quality score of 50% or more were considered to be high quality (low risk of bias) and consequently included in the analysis. The evaluation involved screening studies at the title, abstract, and full text levels. A supplementary file provides further details on the critical appraisal process and scoring (Supplementary File 2).

Outcome measurement

The primary outcome variable of this SRMA was the pooled prevalence of arboviral infections in humans and livestock in Ethiopia.

Data extraction, synthesis and statistical analysis

The data extraction of eligible studies was performed by four reviewers (SS, BE, MMT, and NKM) using a Microsoft Excel worksheet. The extracted data includes authors names, publication year, region, study area, setting, study design, approach, population type, laboratory diagnosis method, diagnostic marker, sample size, number and type of arboviruses. The three reviewers meticulously reviewed and verified their extraction results, resolving any discrepancies through discussions and cross-verification of data (Supplementary File 3).

The meta-analysis was performed using STATA version 17.0 software (Stata Corp., College Station, TX). The point estimate and 95% confidence interval of the pooled prevalence of arbovirus was computed. A random-effects model of analysis was used to estimate the pooled prevalence of arboviruses [18]. Cochrane's Q test and I² statistics were used to assess heterogeneity between studies [19], in which an I^2 of more than 75% was considered substantial heterogeneity. A p value of >0.05 was used to declare that the effect was homogeneous. Therefore, to adjust the observed variability, a random effect model was used. The presence of heterogeneity was further analyzed for its source using subgroup analysis, which was computed based on region, study design, approach, type of arbovirus, setting, population type, laboratory diagnostic method, and diagnostic markers. Likewise, metaregression was also conducted to identify the possible source of heterogeneity. Finally, a sensitivity analysis was performed to evaluate the impact of individual studies on the overall pooled estimate using a leave-one-out analysis to examine the influence of a single study on the overall estimate of arboviruses. Furthermore, publication bias was assessed using visual inspection of the symmetry of the funnel plot and Egger's test statistics [20-22].

Result

Literature search and eligible studies

During the initial electronic search and manual search of reference lists, a total of 1957 articles were retrieved. Approximately 541 articles were excluded because of duplication, 1346 studies were excluded by reviewing their title, abstract and body, and 22 articles were excluded because they were not related to the objective or outcome of this study. Finally, after methodological quality assessment, 52 human studies and 6 livestock studies were included in this systematic review, however, seven studies were excluded in the quantitative synthesis or meta-analysis due to their sample size being lower than 30. Thus, 41 and 6 studies among humans and livestock were included in the final analysis, respectively (Figure 1).

Study characteristics

The studies were conducted from 2014 to 2023 in nine national regional states and the two city administrations of Ethiopia. Considering the districts where the studies were conducted in SNNRP (Arba Minch Zuria, South Omo Zone, Mareka district) and the Somalia region (Kabradihar, Dollo, Dollo ado, Adadle, Godey) (Figure 2, Table 1). Only six human studies were case-control, while all animal studies were cross-sectional, and all are published in English. PCR, ELISA, IFT, and PRNT were employed for the detection of arboviruses targeting the RNA of the virus, its antigen, and antibodies (IgG and IgM), however, ELISA was found to be the commonly used method. The maximum sample size from the included studies was 41,162. In all the studies included in the systematic review, a total of 56,057 humans and 3639 livestock were involved. Of the included participants, 2,584 humans were positive by either of PCR, ELISA, IFT, NS1, PRNT, anti-IgG, and anti-IgM, and 980 livestock were positive by anti-IgG antibodies of arboviruses. In human studies, six arboviruses (DENV, YFV, ZIKV, RVF, WNV, and CHIKV) from the three families (Flaviviridae, Bunyaviridae, and Togaviridae) and three genera (Flavivirus, Phlebovirus, and Alphavirus) were reported, while among livestock studies, three arboviruses (RVF, WNV, and SBV) from two families (Bunyaviridae and Flaviviridae) and three genera (Flavivirus, Phlebovirus, and Orthobunyavirus) were reported. The overall risk of bias assessment score of included studies was 82.44% (Table 1).

Epidemiology of Arboviruses in Ethiopia

After the qualitative synthesis, studies with fewer than 30 participants (eight studies) were excluded from quantitative analysis (meta-analysis). Regardless of the diagnostic markers, the overall pooled prevalence of arboviruses was 11.96% (95% CI: 10.82%, 13.09%), and 15.77% (95% CI: 0.45, 31.08%), respectively in human (Figure 3) and livestock (Figs 4, 5). The existence of heterogeneity between studies was assessed by visual (subjective) techniques using the Galbraith plot to check whether all the points lie within the 95% confidence bounds and the Forest plot to check whether the confidence intervals of studies (the summary effects) overlap with each other. To avoid the subjective nature of visual techniques, the I² test was used. Consequently, there was substantial heterogeneity between the included studies in human and livestock studies with an I^2 value of 98.65% and 99.59%, respectively. Therefore, we have used certain strategies to address heterogeneity, such as carrying-out the metaanalysis using the random effect model, followed by exploring the sources of heterogeneity using sensitivity analysis, subgroup analysis, and meta regression. Thus, Galbraith plot revealed the presence of studies that were outside of the 95% confidence interval in human studies and livestock studies. However, in the leave one-out meta-analysis (sensitivity) analysis, none of the omitted analyses were lies outside the confidence interval for combined analysis. As a result, the result was analyzed considering stratification variables through setting, diagnostic methods and markers, approaches used and the type of viruses reported as reported in the following sections.

Arboviruses epidemiology based on diagnostic markers and methodology among humans

A total of 46 prevalence studies for different arboviruses using different diagnostic methods were identified in humans, of which 10 estimated seroprevalence prospectively from 2018 to 2022. The studies covered 6 of the regional states of Ethiopia with an estimated seroprevalence of 2.7% to 22.53%. Furthermore, the overall seroprevalence of IgM in humans was 10.02% (95% CI: 6.44%, 13.61%), with a significant level of heterogeneity ($I^2 =$ 95.72%). Among eighteen [18] studies that were reported arboviruses in humans using IgG detection, 11 were conducted at the community level and all of the 18 studies were prospective studies published from 2018 to 2021 with an estimated seroprevalence of 3.47% to 49.52%. The overall sero-prevalence of IgG in humans was 15.43% (95% CI: 12.11%, 18.75%), with a significant level of heterogeneity ($I^2 = 98.02\%$). Additionally, seven studies with 232 cases were reported arboviruses in two regional



Fig. 1 Flow diagram for the selection process of eligible studies

states (Afar and Somalia) and one city administration (Dire Dawa) of Ethiopia. The estimated prevalence was reported from 12.3% in 2020 to 67.74% in 2019. The overall pooled prevalence of arboviral RNA was 36.82% (95% CI: 14.82%,58.81%) with a similar substantial heterogeneity of serological markers ($I^2 = 97.73\%$). Furthermore, two studies estimated arboviruses using NS1 detection in 2022 and 2023 with an overall pooled prevalence of arboviruses in humans using NS1 detection was 21.45% (95%

CI: -16.75%,59.63%). One the other hand, a single study was performed using PRNT and reported four different arboviruses from the genus Flaviviruses (i.e., DENV, ZIKV, YFV and WNV (Table 2, Figure 6).

Considering the diagnostic methods used for the detection of arboviruses, the predominancy was observed in molecular methods (36.82%) followed by ELISA (17.09%) and IFT (10.44%). Almost all human studies were cross-sectional studies employed a



Fig. 2 Map showing Ethiopian regions for which data were included in the systematic review and meta-analysis created using https://www. mapchart.net/world-subdivisions.html. The depth of different color shading indicates the number of studies performed in each region of SNNPR the country.

prospective approach however, their pooled effect was not statistically varied. Furthermore, there was a significant difference (P < 0.001) in the epidemiology of arbovirus between studies conducted at the clinical settings (17.91%) and the community level (8.49%) (Figure 6). However, all of livestock studies were a prospective and cross-sectional studies conducted at the community level (Table 1).

Geographic distribution and trends of arboviruses among humans and livestock in Ethiopia

Arboviruses among humans were reported in multiple regions of Ethiopia particularly in hottest areas and boundaries of neighboring countries such as Metema and Humera, Dire Dawa, Somalia and Gambella (Figure 7). According to the cumulative meta-analysis, there was a variability of prevalence of arboviruses ranged from 0.04% to 57.9%. It showed that the arbovirus prevalence can vary considerably across different populations, geographical regions, and study settings (Figure 8). The former studies (i.e., studies of 2014 and 2016 were single) but showing the peak level of arbovirus. Likewise, the peak level of arbovirus in humans pooled from multiple studies was reported in 2022(27.68%), 2019 (23.72%), and 2023 (21.71%) (Figure 9).

Among livestock, arboviruses were reported from camels, goats, sheep, and cattle (Table 1). The subgroup analysis for revealed that majority of studies were conducted at SNNRP and Gambella regional states with a pooled prevalence of 4.91% and 6.4%, respectively. Two families and three genera were reported in livestock studies (Table 3).

Types of arboviruses among humans and livestock in Ethiopia

Regardless of the type of diagnostic methods and diagnostic markers used, the overall pooled prevalence of CHIKV, DENV, RVF, WNV, YFV, and ZIKV was 16.69% (7.0%, 26.39%), 23.41% (19.02%, 27.79%), 13.2% (8.39%, 18.01%), 4.43% (1.78%, 7.07%), 10.48% (6.58%, 14.37%), and 7.18% (2.72%, 11.65%), respectively. Three genus and families of arboviruses were reported in humans, of which, the predominant genus/families were Flaviviruses/Flaviviridae, which was found to be reported in 34 studies with an overall pooled prevalence of 12.62% (11.08%, 14.15%; P<0.001) (Figure 10). However, in livestock studies the most frequently reported arboviruses were the Bunyaviridae family, with a pooled prevalence of 21.1% (-2.09%, 44.3%). Half of the studies were RFV, with a pooled prevalence of 9.26%. Moreover, the three reported viruses among livestock were detected using IgG (Table 3). Furthermore, DENV was predominantly reported among 3 studies from Dire Dawa and Tigray region with a pooled prevalence of 48.67% (95% CI: 21.71%-75.63%) and 26.49% (13.11%-39.87%), respectively, while it was reported with high frequency from a single study from both Somalia and Afar region with a prevalence of 57.89% and 41.56%, respectively. Yellow fever was most common in SNNRP reported from four

	ā
	ğ
ī	금
-	£
	sto
	N
-	0
	a
	INS
	Ë
	2
	p
	ğ
	a
	ses
	Ĩ
	Š
-	2
¢	d /
	Š
-	ĕ
	Ē
-	ģ
•	ă
	ě
7	Ĕ
	Ē
	ess
	ass
	5
C	ŝ
-	đ۴
	stu
-	0
-	ď
	ë
;	≒
	S
-	st
•	ē
	aCt
	Jar
(5
,	а,
1	ō
I	ø

	Authors	Publication	Region	District/s	Study	Approach	Study	Diagnostic	Group	Sample	Numb	er of cas	es reporte	þ		Arbovirus	Quality
		year			Design		setting	technique		size	RNA	gM Ig	او +اوM	NS	1 PRNT	type	
_	Woyessa et al. [23]	2014	Dire Dawa	Dire Dawa	CS	Prospective	Clinical	PCR	Human	88	50					DENV	Medium
5	Ahmed et al. [24]	2016	Somali	Godey	S	Retrospec- tive	Clinical	PCR	Human	57	33					DENV	High
ŝ	Ferede et al. [25]	2018	Tigray	Humera and Metema	S	Prospective	Clinical	ELISA	Human	600		114 12	6 40			DENV	High
				Humera	CS	Prospective	Clinical	ELISA	Human	320		55 51	17				
				Metema	S	Prospective	Clinical	ELISA	Human	280		50 75	23				
4	Geleta et al [<mark>26</mark>]	2019	Oromia	Borena	C	Prospective	Clinical	IFT	Human	519		41 11	6			DENV	High
Ś	Eshetu et al. [<mark>27</mark>]	2020	SNNRP	Arba Minch Zuria	C	Prospective	Clinical	IFT	Human	529		42 13	m			DENV	High
9	Gutu et al. [28]	2021	Somali	Kabradihar	2	Prospective	Clinical	PCR	Human	21	15					DENV	Medium
	Akelew et al. [<mark>29</mark>]	2022	Amhara	Gondar	S	Prospective	Clinical	ELISA	Human	200		1				DENV	High
8	Sisay et al. [30]	2022	Dire Dawa	Dire Dawa	CS	Prospective	Clinical	PCR	Human	60	13					DENV	High
6	Mekuriaw et al. [<mark>31</mark>]	2022	Afar	Gewane	S	ı	Clinical	PCR	Human	12	9					DENV	High
10	Mesfin et al. [<mark>32</mark>]	2022	Somali	Dollo	2	ı	Clinical	PCR	Human	20	9					DENV	High
11	Biru et al [33]	2020	Dire Dawa	Dire Dawa	U U	Prospective	Clinical	PCR	Human	10	9					DENV	High
12	Shimelis et al. [34]	2023	SNNRP	Hawassa	C	Prospective	Clinical	ELISA	Human	407				6		DENV	High
13	Tsegaye et al [35]	2018	Amhara, Oromia, SNNRP, Somalia, BG	Multiple	S	Prospective	Commu- nity	ELISA	Human	1643		57			0	DENV	High
4	Sisay et al. [36]	2023	Afar	Multiple	C	Prospective	Clinical	PCR	Human	154	64					DENV	Medium
15	Degifie [37]	2019	Dire Dawa	Dire Dawa	CS	Prospective	Clinical	PCR	Human	62	42					DENV	High

	Authors	Publication	Region	District/s	Study Design	Approach	Study setting	Diagnostic	Group	Sample size	Number o	f cases r	eported		Arbovirus tvne	Quality
		5									RNA IgM	IgG	lgG +lgM	NS1 PRNT	246	
16 17	Ferede et al. [38]	2023	Tigray	Humera and Metema	S	Prospective	Clinical	ELISA	Human	114 60				17 49	DENV	High
	Nigussie et al [<mark>39</mark>]	2020	Oromia	Borena	S	Prospective	Clinical	IFT	Human	519	38	65			YFV	High
18	Endale et al [40]	2020	SNNRP	South Omo Zone	C	Prospective	Commu- nity	ELISA	Human	313		155			ΥFV	High
19	Lilay [41]	2017	SNNRP	South Omo Zone	S	Retrospec- tive	Clinical	ELISA	Human	21	7				ΥFV	High
20	Eshetu et al. [42]	2020	SNNRP	Gamo Gofa zone	CS	Prospective	Clinical	ΕT	Human	529	38	79			ΥFV	High
21	Asebe et al [43]	2021	Gambella	Lare and Itang	C	Prospective	Commu- nity	ELISA	Human	135		4			ΥFV	High
22	Mulchan- dani et al [44]	2019	SNNRP	South Omo Zone	S	Prospective	Commu- nity	ELISA	Human	165	Q				ΥFV	Medium
23	Tsegaye et al [35]	2018	Amhara, Oromia, SNNRP, Somalia, BG	Multiple	S	Prospective	Commu- nity	PRNT	Human	1643		112		10	ΥFV	High
24	Tsegaye et al [35]	2018	Amhara, Oromia, SNNRP, Somalia, BG	Multiple	S	Prospective	Commu- nity	PRNT	Human	1643		91		15	NNM	High
25	Eshetu et al. [45]	2020	SNNRP	Arba Minch Zuria	CS	Prospective	Clinical	ΕT	Human	529	24	39			MNV	High
26	Nigussie et al [46]	2021	Oromia	Borena	S	Prospective	Clinical	ΕŢ	Human	519	4	38			MNV	High
27	Tsegaye et al [35]	2018	Amhara, Oromia, SNNRP, Somalia, BG	Multiple	S	Prospective	Commu- nity	PRNT	Human	1643		65		7	ZIKV	High
28	Asebe et al [43]	2021	Gambella	Lare and Itang	CS	Prospective	Commu- nity	ELISA	Human	150		41			ZIKV	High
29	lbrahim et al [<mark>47</mark>]	2021	Somali	Adadle	S	Prospective	Commu- nity	ELISA	Human	190		25			RVF	High

Name Name </th <th></th> <th>Authors</th> <th>Publication</th> <th>Region</th> <th>District/s</th> <th>Study</th> <th>Approach</th> <th>Study</th> <th>Diagnostic</th> <th>Group</th> <th>Sample cize</th> <th>Numb</th> <th>er of ca:</th> <th>ses reported</th> <th>_</th> <th>Arbovirus</th> <th>Quality</th>		Authors	Publication	Region	District/s	Study	Approach	Study	Diagnostic	Group	Sample cize	Numb	er of ca:	ses reported	_	Arbovirus	Quality
0 decise (a) (4) 201 demolia (a) (a) (a) (a) (b) C (a) (b) (a) (a) (b) C (a) (b) (a) (a) (b) C (a) (b) (a) (a) (a) (a) (a) (a) (a) (a) (a) (a)			ycai			libicad						RNA	IgM Ig	g lgG +lgM	NS1 PRNT		
31 Gelde, 200 NWP SouthOme G5 Prospective Gymun- ELS Human 360 157 CH8V Meduran 32 Gelea 200 Disa CH8V SouthOme G5 Reconstruction CH8V Meduran 33 Gelea 200 Disa CH8V Human G5 Human G5 G40V Human G6 G40V Heduran 34 Gelea 200 Disa CS Respective Cincial ELS Human G2 13 23 13 23 CH8V Heduran 34 Gelea CS Prospective Cincial ELS Human 174 23 13 23 CH8V Heduran 48366 CS Prospective Cincial ELS Human 14 23 13 23 CH8V Heduran 48366 CS Prospective Cincial ELS Human 14 23 13 24 CH8V Heduran 48366 CS SouthOme CS Prospective Cincial	30	Asebe et al [43]	2021	Gambella	Lare and Itang	CS	Prospective	Commu- nity	ELISA	Human	06		4			CHIKV	High
2 Gelation and the sector Date beam Dire beam	31	Endale et al [40]	2020	SNNRP	South Omo Zone	S	Prospective	Commu- nity	ELISA	Human	360		u) (1		CHIKV	High
31 Feedee 101 Tigay Humer C5 Prospective Elick Human 86 132 31 28 C4 Hup 4 Herman C5 Prospective Elick Human 24 29 13 12 20 CHIV Hip 34 Herman C5 Prospective Elick Human 24 20 13 12 CHIV Hip 4asteil 2020 Sonali Dolo ado CC Prospective Enick Human 51 31 26 14 Hip 14 14 15 CHIV Hip	32	Geleta et al [48]	2020	Dire Dawa	Dire Dawa	S	Retrospec- tive	Clinical	PCR	Human	41162	16				CHIKV	Medium
Meternal CS Prospective Clinical ELSA Human 274 82 16 Clinical ELM Human 214 Clinical ELM Human 214 213 123 Clinical ELM Human 214 213 213 Clinical Human 213 213 213 213 214 214 214 214 214 214 214 214 214 214	33	Ferede et al. [49]	2021	Tigray	Humer- Metema	S	Prospective	Clinical	ELISA	Human	586		132 31	28		CHIKV	High
34 Time C3 Prospective Clinical EGA 99 12 12 CHIN Huph 34 Time 200 Somai Doloado CC Prospective Clinical PCR Human 99 14 C CHIN Medium 4ssets 200 Somai Mareka CC Prospective Clinical PCR Human 14 S CHIN Medium 36 Assets 200 Somai Kehrlichar CC Prospective Clinical PCR Human 14 S CHIN Medium 36 Assets 200 Somai Kehrlichar CC Prospective Clinical PCR Human 14 S CHIN Medium PC					Metema	S	Prospective	Clinical	ELISA	Human	274		32 15	16		CHIKV	High
34 Takete 2020 Somali Dolo ado CC Prospective Clinical PC Human 94 14 CHick Medure Assertid 2020 SNNP Markia CC Prospective Clinical PCR Human 14 8 CHick High					Humera	S	Prospective	Clinical	ELISA	Human	312		50 13	12		CHIKV	High
Assets ciel[51]200SNRPMareka districtCCProspectiveClinicalPCRHuman14BCHKVHigh36etal[51]200SonaliKebricharCCProspectiveCinicalPCRHuman53CHKVHigh36Asebe2020GambellaLareCSProspectiveComuu-ELSALivestok ¹ 36822CHKVHigh37Erables2020GambellaLareCSProspectiveComuu-ELSALivestok ¹ 39722CHKVHigh38etal[53]2020GambellaLareCSProspectiveComuu-ELSALivestok ¹ 397220ProspHigh38etal[54]2020GambellaLareCSProspectiveComuu-ELSALivestok ¹ 39722ProspProsp39Erables2020South OmoCSProspectiveComuu-ELSALivestok ¹ 3972ProspProsp30Erables2021South OmoCSProspectiveComuu-ELSALivestok ¹ 3972ProspProsp31AriaMultipleCSProspectiveComuu-ELSALivestok ¹ 3972ProspProsp32South OmoCSProspectiveComuu-ELSALivestok ¹ 13797ProspProsp33	34	Takele et al [<mark>50</mark>]	2020	Somali	Dolo ado	CC	Prospective	Clinical	PCR	Human	66	14				CHIKV	Medium
31 Alayu 2020 Somali Kebridhar CC Prospective Clincial PCB 3 CHIKV High 32 Revelation Criv Criv C Prospective Clincial PCB 202 CHIKV High 37 Erail[53] Combella Lare C5 Prospective Communic ELISA Livestok ¹ 36 28 RFV High 38 Aeebe 2020 Gambella Lare C5 Prospective Communic Elission 20 RFV High 39 Ketel 2020 Gambella Lare C5 Prospective Communic Elission 20 20 MVV High 30 Ketel 2010 Gambella Lare C5 Prospective Eliston 20 20 20 20 20 20 20 MVV High 30 Ketel Clive CS Prospective Communic Elisson 20 20 20 20 20 20 20 2		Aassefa et al [<mark>51</mark>]	2020	SNNRP	Mareka district	U U	Prospective	Clinical	PCR	Human	14	00				CHIKV	High
36 Asebe 2020 Gambella Lare C5 Prospective Community ELAs Livestok ¹ 36 28 RFV High 37 Endale 2021 SNNRP SouthOmo C5 Prospective Community ELAs Livestok ¹ 36 20 RFV High 38 Asebe 2020 Gambella Lare C5 Prospective Community ELAs Livestok ¹ 368 20 RFV High 39 Endale 2021 Gambella Lare C5 Prospective Community ELSA Livestok ¹ 368 20 RFV High 30 Endale 2021 SouthOmo C5 Prospective Community 1379 780 RFV High 40 Sibhat 2018 Ani, Multiple C5 Prospective Community 1379 780 60 Mol 41 Ibrahim 2021 SouthOmo C5 Prospective Community 110 780 50 50 50 <td>35</td> <td>Alayu et al [<mark>52</mark>]</td> <td>2020</td> <td>Somali</td> <td>Kebridhar City</td> <td>CC</td> <td>Prospective</td> <td>Clinical</td> <td>PCR</td> <td>Human</td> <td>5</td> <td>ŝ</td> <td></td> <td></td> <td></td> <td>CHIKV</td> <td>High</td>	35	Alayu et al [<mark>52</mark>]	2020	Somali	Kebridhar City	CC	Prospective	Clinical	PCR	Human	5	ŝ				CHIKV	High
37 Endale 201 SNNP SouthOmo C5 Pospective Comunity Hostok ¹ 36 20 MPV High 38 Asebe 2020 Gambella Late C5 Pospective Comunity ELSA Livestok ¹ 365 20 WNV High 39 Asebe 2020 Gambella Late C5 Pospective Comunity ELSA Livestok ¹ 365 20 WNV High 30 Endale 201 SNNR SouthOmo C5 Pospective Comunity 1379 19 MVV High 40 Sibhat 2018 MA, Multiple C5 Pospective Comunity 1379 780 780 MVV High 40 Sibhat 2018 Multiple C5 Pospective Comunity 10 19 10 <	36	Asebe et al [53]	2020	Gambella	Lare	S	Prospective	Commu- nity	ELISA	Livestok ¹	368		26	~		RFV	High
38 Asebe 2020 Gambella Lare C5 Pospective Comunity 164 36 20 WNV High 39 Endale 2021 SNNR South Omo C5 Pospective Comunity Livestok ¹ 397 19 WNV High 40 Sibhat 2018 Aa, Multiple C5 Pospective Comunity Livestok ¹ 1379 780 Reduum High 41 Ibrahim 2021 Somali Adale C5 Pospective Comunity Livestok ¹ 1379 780 Reduum Reduum 41 Ibrahim 2021 Somali Adale C5 Pospective Comunity Livestok ¹ 1379 780 Reduum Reduum 41 Ibrahim 2021 Somali Adale C5 Pospective Comunity Livestok ¹ 1379 780 Reduum Reduum 41 Ibrahim 2021 Somali Adale C5 Pospective Livestok ¹ 139 Reduum Reduum <	37	Endale et al [<mark>54</mark>]	2021	SNNRP	South Omo Zone	S	Prospective	Commu- nity	ELISA	Livestok ¹	397		20	~		RFV	High
39 Endale 2021 SNNRP South Omo CS Prospective Livestok 397 19 WIV High 40 Sibhat 2018 AA, Multiple CS Prospective Comula, 1379 780 SBV Medium 40 Sibhat 2018 AA, Multiple CS Prospective Comula, 1379 780 SBV Medium 41 Ibrahim 2021 Somali Adadle CS Prospective Comula, 1379 780 RFV High 41 Ibrahim 2021 Somali Adadle CS Prospective Comula, 1379 780 RFV High 41 Ibrahim 2021 Somali Adadle CS Prospective Comula, 10 RFV High 41 Ibrahim 2021 Somali Adadle CS Prospective Investok ² 141 60 RFV High 41 Intestok ² 252 15 15 RFV RFV High </td <td>38</td> <td>Asebe et al [<mark>53</mark>]</td> <td>2020</td> <td>Gambella</td> <td>Lare</td> <td>S</td> <td>Prospective</td> <td>Commu- nity</td> <td>ELISA</td> <td>Livestok¹</td> <td>368</td> <td></td> <td>20</td> <td>~</td> <td></td> <td>NNN</td> <td>High</td>	38	Asebe et al [<mark>53</mark>]	2020	Gambella	Lare	S	Prospective	Commu- nity	ELISA	Livestok ¹	368		20	~		NNN	High
40 Sibhat 2018 AA, Multiple CS Prospective Cumu- ELISA Livestok ¹ 1379 780 SBV Medium 41 Brahim 2021 Somali Adadle CS Prospective Cumu- ELISA Livestok ² 141 60 RFV High 41 Ibrahim 2021 Somali Adadle CS Prospective Cumu- ELISA Livestok ² 141 60 RFV High 41 Ibrahim 2021 Somali Adadle CS Prospective Cumu- ELISA Livestok ² 141 60 RFV High 41 Ivestok ³ 252 15 17 RFV High 41 Ivestok ³ 252 15 17 RFV High 41 Ivestok ³ 252 15 17 RFV High 41 Ivestok ³ 256 74 245 136 8 41	39	Endale et al [<mark>54</mark>]	2021	SNNRP	South Omo Zone	C	Prospective	Commu- nity	ELISA	Livestok ¹	397		10	~		MNV	High
41 Ibrahim 2021 Somali Adadle CS Prospective Commun- ELSA Livestok ¹ 108 19 RFV High et al [47] nity Livestok ² 141 60 RFV High Livestok ³ 252 15 RFV High Livestok ⁴ 229 17 RFV High S5656 276 276 28 41	40	Sibhat et al [<mark>55</mark>]	2018	AA, Oromia, SNNRP	Multiple	S	Prospective	Commu- nity	ELISA	Livestok ¹	1379		75	00		SBV	Medium
etal [4/] Etal [4/] Etal [4/] Etal [4/] Etal [4/] High Livestok ² 252 15 15 RFV High Livestok ⁴ 229 17 RFV High 159696 276 744 2445 136 58 41	41	Ibrahim	2021	Somali	Adadle	CS	Prospective	Commu-	ELISA	Livestok ¹	108		10	~		RFV	High
Livestok ³ 252 15 RFV High Livestok ⁴ 229 17 RFV High 59696 276 744 245 136 58 41		et al [4/]						nity		Livestok ²	141		90	_		RFV	High
Livestok ⁴ 229 17 RFV High 59696 276 744 2445 136 58 41										Livestok ³	252		- - -			RFV	High
59696 276 744 2445 136 58 41										Livestok ⁴	229		17			RFV	High
											59696	276	744 24	45 136	58 41		
	Nile	Virus; YFV: Y ₆	ellow Fever Virus; 2	ZIKV: Zika Virt	us												

Table 1 (continued)

Study			-		Prevalence with 95% CI	Weight (%)
Degifie, 2019						0.74
Nigussie et al, 2020	•				7.30 [5.06, 9.54]	2.92
Tsegaye et al, 2018	•	-			5.50 [4.39, 6.61]	3.19
Eshetu et al., 2020	•				7.20 [5.00, 9.40]	2.93
Tsegaye et al, 2018	•				6.80 [5.58, 8.02]	3.17
Endale et al, 2020					43.60 [38.48, 48.72]	1.97
Tsegaye et al, 2018	•				0.90 [0.44, 1.36]	3.27
Akelew et al., 2022					20.50 [14.91, 26.09]	1.83
Asebe et al, 2021			_		27.30 [20.17, 34.43]	1.43
Ferede et al., 2020					22.50 [19.12, 25.88]	2.55
Tsegaye et al, 2018	•				3.50 [2.62, 4.38]	3.23
Tsegaye et al, 2018	•				4.00 [3.06, 4.94]	3.22
Eshetu et al., 2020		•			14.90 [11.86, 17.94]	2.66
Sisay et al., 2023			— — —		41.60 [33.82, 49.38]	1.29
Tsegaye et al, 2018	•				0.50 [0.14, 0.86]	3.28
Eshetu et al., 2020	•				7.40 [5.17, 9.63]	2.92
Ferede et al., 2020	•				5.30 [3.49, 7.11]	3.04
Tsegaye et al, 2018	•				0.40 [0.09, 0.71]	3.28
Tsegaye et al, 2018	•				0.60 [0.22, 0.98]	3.28
Geleta et al, 2019					22.90 [19.28, 26.52]	2.47
Woyessa et al., 2014					56.80 [46.45, 67.15]	0.88
Ahmed et al., 2016					57.90 [45.08, 70.72]	0.63
Ibrahim et al, 2021	-	.			13.20 [8.39, 18.01]	2.07
Ferede et al., 2018		• • •			19.00 [15.86, 22.14]	2.63
Asebe et al, 2021	-				15.60 [8.11, 23.09]	1.35
Endale et al, 2020			- •	⊢	49.50 [43.96, 55.04]	1.84
Ferede et al., 2022					41.20 [32.36, 50.04]	1.10
Shimelis et al., 2023	•				2.20 [0.77, 3.63]	3.13
Eshetu et al., 2020					25.10 [21.40, 28.80]	2.44
Mulchandani et al, 2019	•				3.60 [0.74, 6.46]	2.72
Asebe et al, 2021	•				3.00 [0.14, 5.86]	2.72
Sisay et al., 2022		-	-		21.70 [11.28, 32.12]	0.87
Eshetu et al., 2020	•				4.50 [2.73, 6.27]	3.05
Nigussie et al, 2020	•				2.70 [1.31, 4.09]	3.13
Geleta et al, 2019	•				7.90 [5.58, 10.22]	2.89
Ferede et al., 2018					21.00 [17.74, 24.26]	2.59
Eshetu et al., 2020	•				7.90 [5.60, 10.20]	2.90
Takele et al, 2020		-			14.10 [7.24, 20.96]	1.49
Nigussie et al, 2020		•			12.50 [9.65, 15.35]	2.73
Nigussie et al, 2020	•	I I			7.30 [5.06, 9.54]	2.92
Geleta et al, 2020	•				0.04 [0.02, 0.06]	3.29
Overall		•			11.96 [10.82, 13.09]	
Heterogeneity: τ^2 = 10.17, I^2 = 98.65%, H^2 = 73.92						
Test of $\theta_i = \theta_j$: Q(40) = 2956.73, p = 0.00						
Test of θ = 0: z = 20.66, p = 0.00						
	0	20	40	60	80	

Pooled prevalence of arboviruses among humans in Ethiopia

Random-effects DerSimonian–Laird model

Fig. 3 Forest plot showing pooled prevalence of arboviruses among humans in Ethiopia



Pooled prevalence of Arboviruses among livestock in Ethiopia

Random-effects DerSimonian-Laird model

Fig. 4 Forest plot showing pooled prevalence of arboviruses IgM seroprevalence among livestock in Ethiopia



Fig. 5 Forest plot showing pooled prevalence of arboviruses IgM seroprevalence among livestock in Ethiopia

studies with a pooled prevalence of 18.71%, and CHIKV virus was most frequently reported from SNNRP, Gambella and Somalia respectively. Additionally, WNV was predominant in SNNRP and Oromia with a pooled prevalence of 5.86% and 4.92%, respectively.

Meta-regression analyses

To investigate the impacts of active potential factors in the heterogeneity of prevalence of arboviruses in Ethiopia, a random-effects meta-regression test has been done using the DerSimonian–Laird method. Furthermore, meta-regression analysis was computed with each potential factors and covariates individually with the effect size. Diagnostic markers ($R^2 = 1.90\%$), quality of studies ($R^2 =$

Table 2 Pooled	prevalence of a	arboviruses among	humans in Ethio	pia usinc	different dia	gnostic markers

Arbovirus markers	Number of studies	Number of cases	PP (95% CI)	l ²	н	<i>p</i> -value
Humans						
- IgG seroprevalence	18	1465	15.43(12.11, 18.75)	98.02	50.52	<0.001
- IgM seroprevalence	11	136	10.02(6.44, 13.61)	95.72	23.34	<0.001
- NS1	2	58	21.45(-16.77, 59.66)	98.63	72.86	<0.001
- PRNT	1*	41	0.56(0.37, 0.75)	7.36	1.08	0.36
- Viral RNA prevalence	7	232	36.82(14.82,58.81)	97.73	44.07	0.001
Livestock						
- IgG seroprevalence	6	980	15.77(0.45, 31.08)	99.59	246.39	<0.001

1*: one article assessed four viruses (DENV, ZIKV, YFV and WNV), *PRNT* plaque reduction neutralization tests, *NS1* Non-structural protein-1, *PP* pooled prevalence, *CI* confidence interval, *H* Cochrane Q, chi square for heterogeneity, *Ig* immunoglobulin; *P*<0.01: Significant heterogeneity.

			Prevalence	
Study	Number of studies		with 95% CI	p-value
Design				
CC	1	- ₽-	14.10 [7.24, 20.96]	0.000
CS	40		11.91 [10.77, 13.05]	0.000
Test of group	p differences: $Q_b(1) = 0.38$, p = 0.54			
Approach				
Prospective	39		13.33 [11.80, 14.86]	0.000
Retrospectiv	ve 2		28.60 [-28.10, 85.30]	0.323
Test of group	p differences: $Q_b(1) = 0.28$, p = 0.60			
Setting				
Clinical	26		17.91 [14.59, 21.24]	0.000
Community	15	•	8.49 [6.83, 10.15]	0.000
Test of grou	p differences: $Q_b(1) = 24.68$, p = 0.00			
Diagnostic	Method			
ELISA	17		17.09 [13.17, 21.01]	0.000
IFT	12	4	10.44 [7.31, 13.57]	0.000
PCR	7		<u> </u>	0.001
PRNT	5	•	1.13 [0.45, 1.82]	0.001
Test of group	p differences: $Q_b(3) = 100.35$, p = 0.00			
Marker				
lgG	18	•	15.43 [12.11, 18.75]	0.000
lgM	10	4	10.02 [6.44, 13.61]	0.000
NS1	2		21.45 [-16.77, 59.66]	0.271
PRNT	4	•	0.56 [0.37, 0.75]	0.000
RNA	7	· · · · ·	— 36.82 [14.82, 58.81]	0.001
Test of group	p differences: $Q_b(4) = 114.77$, p = 0.00			
Overall			11.96 [10.82, 13.09]	0.000
Heterogenei	ty: $\tau^2 = 10.17$, $I^2 = 98.65\%$, $H^2 = 73.92$			
Test of $\theta_i = \theta_i$	9 _j : Q(40) = 2956.73, p = 0.00			
		-50 0	50 100	

Random-effects DerSimonian-Laird model

Fig. 6 Forest plot showing subgroup analysis of arboviruses by study design, approach, diagnostic method and markers among humans in Ethiopia

64.72%), publication year ($R^2 = 59.70\%$), sample size ($R^2 = 62.11\%$), approaches used ($R^2 = 63.48\%$), setting ($R^2 = 72.92\%$), and type of viruses ($R^2 = 42.66\%$) were significantly explained (*P*<0.005) heterogeneity between studies

among humans. Furthermore, in livestock studies, heterogeneity was statistically explained by the two covariates (publication year and sample size) and one factor (quality of studies) with an \mathbb{R}^2 of greater than 89% (Table 4).

						Prevalence	
Study	К					with 95% CI	p-value
Region							
Afar	1				_	41.60 [33.82, 49.38]	0.000
Amhara	1					20.50 [14.91, 26.09]	0.000
Amhara, Oromia, SNNRP, Somalia, BG	8	•				2.65 [1.56, 3.75]	0.000
Dire Dawa	4			•		36.32 [0.68, 71.97]	0.046
Gambella	3		•			15.05 [-0.35, 30.44]	0.055
Oromia	6		-			9.93 [5.31, 14.56]	0.000
SNNRP	10	-	-			16.22 [9.91, 22.53]	0.000
Somali	3	-	•			27.34 [7.71, 46.97]	0.006
Tigray	5		•			21.21 [11.73, 30.69]	0.000
Test of group differences: $Q_b(8) = 169.36$,	p = 0.00						
Districts							
Adadle	1	-	•			13.20 [8.39, 18.01]	0.000
Arba Minch Zuria	4		<u> </u>			11.05 [4.35, 17.74]	0.001
Borena	6	-	-			9.93 [5.31, 14.56]	0.000
Dire Dawa	4			•		36.32 [0.68, 71.97]	0.046
Dolo ado	1	-	•			14.10 [7.24, 20.96]	0.000
Gamo Gofa zone	2		<u> </u>			10.98 [3.43, 18.52]	0.004
Godey	1			-	•	57.90 [45.08, 70.72]	0.000
Gondar	1					20.50 [14.91, 26.09]	0.000
Hawassa	1	•				2.20 [0.77, 3.63]	0.003
Humera and Metema	5		•			21.21 [11.73, 30.69]	0.000
Lare and Itang	3		•			15.05 [-0.35, 30.44]	0.055
Multiple	9	+				3.56 [2.28, 4.85]	0.000
South Omo Zone	3			•		32.17 [0.07, 64.27]	0.049
Test of group differences: $Q_b(12) = 160.88$	3, p = 0.00						
Overall						11.96 [10.82, 13.09]	0.000
Heterogeneity: $\tau^2 = 10.17$, $I^2 = 98.65\%$, H^2	= 73.92						
Test of $\theta_i = \theta_j$: Q(40) = 2956.73, p = 0.00							
		0	20	40	60	80	

Random-effects DerSimonian-Laird model

Fig. 7 Forest plot showing distribution of arboviruses among humans in Ethiopia by region and districts

Publication bias

To check the publication bias, funnel plot analysis was performed. The asymmetry of the funnel plot in the figure below indicates the presence of publication bias (Supplementary file-4). To avoid the subjective nature of visual inspection of the asymmetric distribution of the studies, Egger's test statistics was performed, and the presence of publication bias was confirmed for both humans and livestock studies with *p*-value of less than 0.001 and 0.024, respectively. Thus, the non-parametric trim and fill analysis was performed. Four additional articles were imputed in humans yielding the total number of articles to be 45 with a pooled prevalence of 12.72% (95% CI: 10.67%, 14.01%). Similarly, in livestock studies, two articles were imputed and the total number of studies reached 8 with a pooled prevalence of 21.2% (7.72%, 34.68%). Fortunately, the pooled prevalence of the final model (observed and imputed) wasn't significantly differed from the observed value (Table 5).

Discussion

Arbovirus infections have continued to be a global burden of climate-sensitive vector borne infectious diseases, particularly in resource-limited countries, including Ethiopia, where sufficient diagnostic facilities aren't available. The increased prevalence rate of arbovirus infections

Prevalence Study with 95% CI p-value prevalence 2014 56.80 [46.45, 67.15] 0.000 56.8 Wovessa et al., 2014 2016 Ahmed et al., 2016 57.90 [45.08, 70.72] 0.000 57.9 2018 Tsegaye et al, 2018 0.40 [0.09, 0.71] 0.013 4 Tsegave et al. 2018 0.44 [0.21. 0.681 0.000 .5 Tsegave et al. 2018 • 0.49 [0.29, 0.691 0.000 .6 0.000 • 0.37, 0.751 Tsegaye et al, 2018 0.56 [.9 • 1.05 [0.43. 0.001 Tsegaye et al, 2018 1.681 3.5 Tsegave et al, 2018 1.53 [0.73. 2.321 0.000 4 Tsegave et al, 2018 2.08 [1.12. 3.031 0.000 5.5 2.65 [3.751 Tsegave et al, 2018 1.56. 0.000 6.8 2.55, 0.000 Ferede et al., 2018 3.84 [5.131 19 Ferede et al., 2018 0.000 5.19 [3.75 6.641 21 2019 0.74, 6.46] Mulchandani et al, 2019 3.60 [0.013 3.6 Geleta et al, 2019 5.83 [1.62, 10.04] 0.007 7.9 1.47, 21.31] Geleta et al, 2019 11.39 [0.024 22.9 Degifie, 2019 23.72 [10.65, 36.79] 67.7 0.000 2020 0.06] Geleta et al, 2020 0.04 [0.02, 0.000 .04 1.27 [-1.33, 3.88] 0.337 Nigussie et al, 2020 2.7 Eshetu et al., 2020 2.31 [-0.48, 5.10] 0.105 45 Ferede et al., 2020 3.05 I 0.23, 5.87] 0.034 53 Eshetu et al., 2020 3.85 [0.94, 6.77] 0.010 72 Nigussie et al. 2020 4 4 2 T 1.52, 7.321 0.003 73 Nigussie et al. 2020 4.83 I 1.98. 7.671 0.001 7.3 Eshetu et al., 2020 5.15 I 2.37, 7.93] 0.000 7.4 2.72, 5.45 I Eshetu et al., 2020 8.18] 0.000 7.9 3.30, 6.13 I Nigussie et al. 2020 8.96] 0.000 12.5 3.84, Takele et al. 2020 6.63 [9.411 0.000 14.17.34 I 4.43, 10.24] Eshetu et al., 2020 0.000 14.9 5.33, 11.71] Ferede et al., 2020 8.52 [0.000 22.5 Eshetu et al., 2020 9.70 [6.28, 13.12] 0.000 25.1 Endale et al. 2020 11.84 ſ 8.04, 15.64] 0.000 43.6 14.09 [9.96, 18.23] 49.5 Endale et al. 2020 0.000 2021 Asebe et al, 2021 3.00 [0.14, 5.86] з 0.040 Ibrahim et al, 2021 7.91 [-2.08, 17.90] 0.121 13.2 Asebe et al, 2021 10.17 [1.71, 18.64] 0.019 15.6 4.20, 24.68] Asebe et al, 2021 14.44 [0.006 27.3 2022 20.50 [14.91, 26.09] 0.000 Akelew et al., 2022 20.5 Sisay et al., 2022 20.77 [15.84, 25.70] 0.000 217 27.68 [14.50, 40.85] 0.000 Ferede et al., 2022 412 2023 Shimelis et al., 2023 2.20 [0.77, 3.63] 0.003 2.2 Sisay et al., 2023 21.71 [-16.90, 60.32] 0.271 41.6 -50 ò 50 100

Trends of arboviruses among humans in Ethiopia

Random-effects DerSimonian-Laird model

Fig. 8 Forest plot showing cumulative meta-analysis of arboviruses among humans in Ethiopia

Arbovirus markers	Category	Number of studies	PP (95% CI)	²	<i>p</i> -value
Regions	AA, Oromia and SNNRP	1	56.56(53.94, 59.18)	0.0	0.87
	Gambella	2	6.4(4.28, 8.53)		
	SNNRP	2	4.91(3.41, 6.41)		
	Somalia	1	15.21(12.61, 17.81)		
Viruses	RVF	3	9.26(3.21, 15.31)	78.25	0.048
	SBV	1	56.56(53.94, 59.18)		
	WNV	2	5.08(3.52, 6.63)		
Quality	High	5	7.57(3.94, 11.2)	91.59	<0.001
	Medium	1	56.56(53.94, 59.18)		

Table 3 Subgroup analysis of arboviruses among livestock in Ethiopia

AA Addis Ababa, RFV Rift Valley Fever, SBV Schmallenberg virus, SNNRP Southern Nations Nationalities and People's Region, WNV West Nile Virus



Fig. 9 Prevalence of arboviruses in humans over time in Ethiopia. The graph is created by chart.js library.

alarms the need for immediate intervention strategies from the interface of human and animal health. Thus, this systematic review and meta-analysis provides a comprehensive overview of the epidemiology of arboviruses in humans and livestock in Ethiopia. This study provides critical insights into the dynamics of these zoonotic diseases and further highlights the significant burden and widespread distribution of arboviruses in both humans and animals across the different regions of the country. A cross-sectional study design coupled with a prospective methodological approach was the most commonly employed design in the included studies. The geographical distribution spanned multiple regions, indicating that arboviruses pose a nationwide public health threat in Ethiopia, however, the most frequent studies were reported from the SNNRP and Somalia regions. Six different arboviruses (DENV, YFV, ZIKV, RVF, WNV, CHIKV) were reported in humans and three in livestock (RVF, WNV, SBV), representing the diverse viral families and genera.

In this SRMA, the pooled prevalence of arboviral RNA, IgG, and IgM sero-prevalence among humans was 38.42%, 15.43%, and 10.04%, respectively. This indicates that for every six, ten and three suspected

individuals, at least one individual can have an arboviral infections based on IgG, IgM and viral RNA detection. Moreover, this finding implies that there is a need for robust and nationwide surveillance and early warning systems; expansion of diagnostic capacities or facilities for early detection of arboviruses across the region; integrated vector control programs tailored to the local ecological contexts; integrated multi-sectoral collaborations working in the same vein as the One Health approach; and climate change consideration. Therefore, the national-level public health policies should focus on evidence-based integrated arbovirus surveillance and control, explore the potential of cross-border transmission dynamics of arboviruses, and international collaboration for integrated control. Moreover, a planetary health approach could be an important approach to control anthropogenic activities such as urbanization, land use change, and deforestation, all of which aggravate the extent of climate change and the circulation of arboviruses [1, 7]. On the other hand, the wide spread distribution of arboviruses suggests a significant economic burden on the healthcare system and the affected individuals. Thus, for an integrated arbovirus prevention and control program, funding is crucial,

				Prevalence	
Study	Number of studies			with 95% CI	p-value
Types of Viruse	es				
Chikungunia	6			16.69 [7.00, 26.39]	0.001
Dengue	16			23.41 [19.02, 27.79]	0.000
RVF	1			13.20 [8.39, 18.01]	0.000
West nile	5			4.43 [1.78, 7.07]	0.001
Yellow fever	10			10.48 [6.58, 14.37]	0.000
Zika	3			7.18 [2.72, 11.65]	0.002
Test of group dif	ferences: $Q_b(5) = 58.04$, p = 0.00				
Genus/Family					
Phlebovirus/Bun	yaviridae 1			13.20 [8.39, 18.01]	0.000
Flavivirus/Flaviv	iridae 34			12.62 [11.08, 14.15]	0.000
Alphavirus/Toga	viridae 6			16.69 [7.00, 26.39]	0.001
Test of group dif	ferences: Q _b (2) = 0.70, p = 0.71				
Quality of studi	es				
High	35			12.64 [11.09, 14.19]	0.000
Medium	6		•	- 21.90 [10.58, 33.22]	0.000
Test of group dif	ferences: $Q_b(1) = 2.52$, p = 0.11				
Overall		•		11.96 [10.82, 13.09]	0.000
Heterogeneity: T	² = 10.17, I ² = 98.65%, H ² = 73.92				
Test of $\theta_i = \theta_j$: Q	(40) = 2956.73, p = 0.00			_	
		0 10	20 30		

Random-effects DerSimonian-Laird model

Fig. 10 Forest plot showing distribution of arboviruses among humans in Ethiopia by type of pathogen and quality of studies

Table 4	Meta-regression ana	lysis of	potential factors and co	variates of Arboviruses am	ong humans and li	vestock in Ethiopia
		/				

Category	Covariates	Coefficient	95% Cl	R ² (%)	l ²	Р
Arboviruses in humans	Quality of studies	8.805708	4.96269, 12.64873	64.72	100.0	<0.001
	Publication year	-1.069989	-1.91126, -0.22873	59.70	100.0	0.013
	Sample size	0.264783	0.100145, 0.34176	62.11	100.0	0.025
	Approach	18.69573	12.28022, 25.11125	63.48	100.0	<0.001
	Study area/district	-0.1736615	-0.3621052, 0.0147821	70.56	100.0	0.071
	Setting	-8.574682	-11.04537, -6.103994	72.92	100.0	<0.001
	Diagnostic marker	3.702445	2.213595, 5.191295	1.9	100.0	<0.001
	Virus type	-3.672766	-4.724589, -2.620943	42.66	100.0	<0.001
	Region	0.8667409	-0.0464061, 1.779888	24.20	100.0	0.063
lgG seroprevalence in Livestock	Quality of studies	48.99059	40.03358, 57.9476	95.7	91.59	<0.001
	Publication year	-15.19463	-23.06647, -7.322777	70.24	98.67	<0.001
	Sample size	0.0496674	0.54115613, 0.0577735	96.65	89.41	<0.001
	Region	-11.56939	-25.74781, 2.609022	21.59	99.05	0.110
	Study area/district	-0.2885099	-15.80802, 15.231	0.0	99.67	0.971
	Virus type	-15.99024	-49.60642, 17.62594	0.0	99.61	0.351
	Family/genus	0.389662	-18.88995, 19.66927	0.0	99.67	0.968

Table 5	Nonparametric trim- and	-fill analysis of publication	on bias for assessing arboviruses ir	humans and livestock in Ethiopia

	Prevalence of Arboviral in human's	Seroprevalence in livestock	
Iteration and pooling Model: Random effects	Observed =41	Observed =6	
Iteration and pooling Method: DerSimonian-Laird	Imputed = 4	Imputed $= 2$	
	Total studies = 45	Total studies = 8	
Pooled result after trim-and -fill analysis			
Number of studies	Prevalence (95% CI)	Prevalence (95% CI)	
Observed	11.96(10.82, 13.09)	15.77(0.45, 31.8)	
Observed + Imputed	12.72(10.67, 14.01)	21.2 (7.72, 34.68)	

which knocks the door of national and international organizations.

ELISA and IFT were the most frequently used diagnostic methods for arbovirus detection, while PCR and PRNT weren't commonly used in Ethiopia. This might be due to the fact that serological tests are easy to use, sensitive, cheap, readily available, and important for understanding population exposures in the past, however, their epidemiological application is limited by the potential for cross-reactivity with antibodies of different arboviruses because of the molecular mimicry of nucleotide homology they share and can be affected by history of vaccination [56-58]. Furthermore, nucleic acid-based tests aren't easily applicable and require sophisticated resources and well-trained expertise unlikely to serological tests. Hence, real-time (quantitative) polymerase chain reaction (qPCR) and plaque reduction neutralization test (PRNT) are required to validate the findings of these serologic assays [59], and confirm outbreaks, but not for routine screening techniques in resource-limited countries like Africa [60].

Subgroup analyses regarding the epidemiological profile of arboviruses were conducted in this study. The most commonly reported arboviruses in humans were DENV, CHIKV, and YFV. The overall pooled IgG seroprevalence of DENV (18.07%) and CHIKV (21.45%) was consistent with the global seroprevalence of Dengue virus (24%) and Chikungunya virus (21.6%) in blood donors [60], however, the present findings of DENV was lower than the pooled seroprevalences of DENV (38%) [61]. This difference might be due to the variations in the time period and number of articles included in the meta-analysis, where it includes 133 articles from 44 countries published from 2000, while the present study articles published from 2014 were included.

The epidemics of YFV in Ethiopia were reported between 1960 and 1962, with an estimate of 100,000 cases and 30,000 deaths [62]. This meta-analysis also documented that the burden of YFV was 14.77% and 6.76%, respectively in IgG and IgM seroprevalence in humans, which was consistent with previously reported 9.4% pooled prevalence of YFV in SSA [63]. This finding revealed that the burden consistently existed across the African region, suggesting ongoing challenges in managing and preventing the disease in the region. Furthermore, considering the cross-border risk of the disease, the finding highlights the urgent need for regional collaboration in the control and prevention of arboviruses in general and YFV in particular.

The overall pooled IgG seroprevalence of ZIKV among humans was 15.37%. The present finding was consistent with the global seroprevalence of ZIKV, 21% in 2024 and 18% in 2021 [61, 64], which further indicates that ZIKV is an existing global burden found in Ethiopia. Moreover, the overall pooled IgG seroprevalence of ZIKV in our study was slightly higher than the seroprevalence of ZIKV, 5.1% [60] and 1.02% [65] among blood donors, which could be varied by their degree of risk exposure differences. Additionally, studies included in this metaanalysis were carried-out among suspected cases, which might contribute to the presence of a slight increment of ZIKV compared to blood donors.

In our meta-analysis, the overall pooled IgG and IgM seroprevalence of WNV in humans was 7.35% and 3.53%, respectively; these pooled values were lower than those met-analysis study reported 76.5% and 7.1% anti-IgG and anti-IgM seroprevalences of WNV in Nigeria [56]. Moreover, the pooled IgG seroprevalence of WNV among livestock in this study (5.08%) was lower than the pooled seroprevalence of WNV (8%) among equids from 16 European countries [66]. This variation might be due to the variations of livestock, where the livestock included in this meta-analysis were only cattle, sheep, goats and camels. This also further suggests the effective surveillance and control measures across the human and animal domains in order to reduce the transmission dynamics of YFV.

RVF (9.26%) was predominantly reported in multiple studies of livestock, but a single report was found in humans. The burden of RVF in livestock's' of the present

meta-analysis was consistent with the 9.3% report of RVF in animals reported from Africa [67]. The existing burden of RVF might have a socio-economic impact both at national and international levels [68] with direct costs of morbidity and death in both humans and animals, which further leads to an economic crisis. Additionally, animal losses can have knock-on effects altering herd dynamics [69].

Meta-regression analysis was used to explore the sources of heterogeneity. Hence, sample size was found to explain the largest source of heterogeneity in IgG seroprevalence studies both in humans and livestock. Likewise, in IgM and viral RNA prevalence, type of viruses was found the influential factors for explaining the sources of heterogeneity between studies. Furthermore, Publication bias was assessed by using the visual funnel plots and statistical Egger's test. Both methods confirmed the presence of publication bias. Thus, non-parametric trim-and -fill analysis was performed but there was no statistical difference between the observed value and final trim- and -fill analysis (observed and imputed) of pooled prevalence of arboviruses in humans and livestock.

Future studies shall focus on circulating arboviruses coupled with vector distribution and association and vaccination status and effectiveness. This study has certain limitations. Thus, caution must be applied when generalizing the pooled estimates to the target population. Although I² is not an absolute measure of heterogeneity, high heterogeneity was observed. This variation might not be solely attributed to publication bias; rather, it might be due to variations in the sample size, diagnostic methodology and markers, and variations in types of arboviruses. Therefore, the random effect model was used to limit the influence of the study heterogeneity, and subgroup analyses, sensitivity analyses, and metaregression were performed to rule out study variability. The meta-regression finding revealed types of diagnostic method, sample size, family/genus, type of viruses and district explained the heterogeneity between studies at different levels.

Conclusion and recommendation

The overall national pooled prevalence of arbovirus infections in humans and livestock in Ethiopia was notable, which alarms the need for immediate multisectoral interventions. DENV, CHIKV, and YFV in humans and RVF and WNV in livestock were the most commonly reported arboviruses. The most commonly employed diagnostic methods for arbovirus infections were serological tests (i.e., ELISA and IFT). Therefore, targeted evidence-based public health interventions are essential to mitigate the risk of arboviral outbreaks. This requires implementing national surveillance systems to monitor the long-term impact of these interventions, and fostering a coordinated, multi-sectoral One Health initiative that integrates human, animal, and environmental health to optimize vector control strategies in light of climate change, alongside the national immunization programs. Anthropogenic activities are blamed to be associated with an increased circulation of arboviruses. Therefore, planetary health, which is a holistic approach encompassing multisystem and multilateral strategies, could be crucial. This approach promotes collaboration among personnel and organizations at various level globally, helping to maintain ecological balance and strengthen arboviral prevention and con-

Abbreviations

trol programs.

CC	Case Control
CS	Cross-sectional
CHIKV	Chikungunya Virus
DENV	Dengue Fever Virus
ELISA	Enzyme-Linked Immunosorbent Assay
FT	Immune Fluorescent Test
gG	Immunoglobulin G
gМ	Immunoglobulin M
NS1	Non-structural protein-1
PCR	Polymerase Chain Reaction
PRISMA	Preferred Reporting Items for Systematic Review and Meta-analysis
PRNT	Plaque Reduction Neutralization Test
RVF	Rift Valley Fever
SBV	Schmallenberg Virus
SNNPR	Southern Nations, Nationalities, and People Region
SSA	Sub-Saharan Africa
WNV	West Nile Virus
YFV	Yellow Fever Virus
ZIKV	Zika Virus

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12879-025-10824-7.

Supplementary file 1. PRISMA Checklist Supplementary file 2. Quality assessment Supplementary file 3. Dataset Supplementary file 4. Funnel plot for assessing the publication bias

Acknowledgements

We acknowledged the authors of the published paper.

Clinical trial number

Not applicable.

Authors' contributions

Gedefie A, Debash H, Kassaw AB, Belete MA, Desale S, Sebsibe S, Tilahun M, Mulatie Z, Shibabaw A, Tesfaye M. involved in the conception and design, data collection, analysis, and interpretation of the data. Gedefie A, Mankelki G, Metaferia Y, Eshetu B, Kassa Y, Ebrahim H, Alemayehu E, Woretaw L, Kebede L, Temesgen MM, and Msganew NK took part in drafting the article or revising it critically for important intellectual content. Finally, all authors read and approve the final manuscript before submission.

Funding

Not applicable.

Data availability

All the datasets used and/or analyzed during the current study are available in the manuscript.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia. ²Department of Biomedical Sciences, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia. ³Department of Environmental Health Sciences, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia. ⁴Department of Biomedical Sciences, College of Medicine and Health Sciences, Samara University, Samara, Ethiopia. ⁵Amhara Public Health Institute Dessie Branch, Dessie, Ethiopia. ⁶Dessie Town Health Office, Dessie, Ethiopia.

Received: 1 October 2024 Accepted: 19 March 2025 Published online: 02 April 2025

References

- 1. Tajudeen YA, Oladipo HJ, Oladunjoye IO, Yusuf RO, Sodiq H, Omotosho AO, et al. Emerging arboviruses of public health concern in Africa: Priorities for future research and control strategies. Challenges. 2022;13(60):1–11.
- Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7.
- Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16(8):935–41.
- Roiz D, Pontifes P, Jourdain F, Diagne C, Leroy B, Vaissière A-C, et al. The rising global economic costs of Aedes and Aedes-borne diseases. 2023.
- Thompson R, Martin Del Campo J, Constenla D. A review of the economic evidence of Aedes-borne arboviruses and Aedes-borne arboviral disease prevention and control strategies. Expert review of vaccines. 2020;19(2):143–62.
- 6. Venter M. Assessing the zoonotic potential of arboviruses of African origin. Curr Opin Virol. 2018;28:74–84.
- Massengo NRB, Tinto B, Simonin Y. One health approach to arbovirus control in Africa: Interests, challenges, and difficulties. Microorganisms. 2023;11(6):1496.
- Marchi S, Trombetta CM, Montomoli E. Emerging and re-emerging arboviral diseases as a global health problem. Public health - emerging and re-emerging issues. InTech; 2018. Available from: http://dx.doi.org/10. 5772/intechopen.77382.
- Caminade C, Medlock JM, Ducheyne E, McIntyre KM, Leach S, Baylis M, et al. Suitability of European climate for the Asian tiger mosquito Aedes albopictus: recent trends and future scenarios. J R Soc Interface. 2012;9(75):2708–17.
- Gibney KB, Jones A, Armien B, Seixas G, Soul B, Bres V, et al. Dengue virus evolution and introduction dynamics in Mozambique. Journal of virology. 2021;95(15):e0042421.
- Simmons CP, Farrar JJ, Nguyen vV, B. W. Dengue. New England Journal of Medicine. 2012;366(9):1423-32.
- Brault AC, Powers AM, Ortiz D, Estrada-Franco JG, Navarro-Lopez R, SC. W. Venezuelan encephalitis emergence: enhanced vector infection from a single amino acid substitution in the envelope glycoprotein. Proc Natl Acad Sci 2007;104(50):4649-54.
- Costa LB, Barreto FKdA, Barreto MCA, Santos THPd, Andrade MdMOd, Farias LABG, et al. Epidemiology and economic burden of chikungunya: a systematic literature review. Tropical Medicine and Infectious Disease. 2023;8(6):301.

- WHO. Global vector control response 2017–2030. Geneva: World Health Organization. 2017.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
- Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. BMC medical research methodology. 2018;18:1–9.
- Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3(3):123–8.
- Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974-8.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
- Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 2019;98(23):e15987.
- Duval S, R. T. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-63.
- 22. Egger M. Smith GD, AN. P Meta-analysis: principles and procedures BMJ. 1997;315(7121):1533–7.
- Woyessa AB, Mengesha M, Kassa W, Kifle E, Wondabeku M, Girmay A, et al. The first acute febrile illness investigation associated with dengue fever in Ethiopia, 2013: A descriptive analysis. Ethiop J Health Dev. 2014;28(3):155–61.
- Ahmed Y, Salah A. Epidemiology of Dengue Fever in Ethiopian Somali Region: Retrospective Health Facility Based Study. Central African Journal of Public Health. 2016;2(2):51-6.
- Ferede G, Tiruneh M, Abate E, Wondimeneh Y, Damtie D, Gadisa E, et al. A serologic study of dengue in northwest Ethiopia: Suggesting preventive and control measures. PLoS Negl Trop Dis. 2018;12(5):e0006430.
- Geleta EN. Serological evidence of dengue fever and its associated factors in health facilities in the Borena Zone. South Ethiopia Res Rep Trop Med. 2019;10:129–36.
- Eshetu D, Shimelis T, Nigussie E, Shumie G, Chali W, Yeshitela B, et al. Seropositivity to dengue and associated risk factors among non-malarias acute febrile patients in Arba Minch districts, southern Ethiopia. BMC Infectious Diseases. 2020;20(639):1–6.
- Gutu MA, Bekele A, Seid Y, Mohammed Y, Gemechu F, Woyessa AB, et al. Another dengue fever outbreak in Eastern Ethiopia-An emerging public health threat. PLoS Negl Trop Dis. 2021;15(1): e0008992.
- Akelew Y, Pareyn M, Lemma, M, Negash M, Bewket G, et al. Aetiologies of acute undifferentiated febrile illness at the emergency ward of the University of Gondar Hospital, Ethiopia. Trop Med Int Health. 2022;27:271-9.
- Sisay C, Waldetensai A, Seyoum M, Asrat Y, Tayachew A, Wossen M, et al. Detection of serotype 1-Dengue fever outbreak in Dire Dawa city, Eastern Ethiopia. Ethiop j public health nutr. 2022;5(1):49–54.
- Mekuriaw W, Kinde S, Kindu B, Mulualem Y, Hailu G, Gebresilassie A, et al. Epidemiological, entomological, and climatological investigation of the 2019 dengue fever outbreak in Gewane district, Afar Region, North-East Ethiopia. Insects. 2022;13(1066):1–13.
- Mesfin Z, Ali A, Abagero A, Asefa Z. Dengue Fever Outbreak Investigation in Werder Town, Dollo Zone, Somali Region. Ethiopia Infect Drug Resist. 2022;15:7207–17.
- Biru M, Geleta D, Tesfaye N, Aleyu M, A. T. Dengue Fever Outbreak Investigation and Response in Dire Dawa City Administration, Ethiopia, Journal of Medicine. Physiology and Biophysics. 2017;2020(63):23–7.
- Shimelis T, Mulu A, Mengesha M, Alemu A, Mihret A, Tadesse BT, et al. Detection of dengue virus infection in children presenting with fever in Hawassa, southern Ethiopia. Sci Rep. 2023;13(1):7997.
- Mengesha Tsegaye M, Beyene B, Ayele W, Abebe A, Tareke I, Sall A, et al. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective. BMC Public Health. 2018;18(1):1011.
- Sisay C, Tadesse A, Workie F, Yizengaw A, Ali A, Yusuf J, et al. Description of serotype 3 dengue fever virus: clinical, surveillance and geographical expansion in the Northeastern Ethiopia, 2023. Sci J Public Health. 2023;11(4):123–31.

- Degife LH, Worku Y, Belay D, Bekele A, Hailemariam Z. Factors associated with dengue fever outbreak in Dire Dawa administration city, October 2015, Ethiopia - case control study. BMC Public Health. 2019;19(1):650.
- Ferede G, Tiruneh M, Abate E, Wondimeneh Y, Tessema B, UG. L. Distribution of Dengue Virus Serotype based on neutralization assay in Northwest Ethiopia Ethiop J Health Biomed Sci. 2023;13(1):13-21.
- Nigussie E, Shimelis T, Eshetu D, Shumie G, Chali W, Aseffa A, et al. SERO-POSITIVITY OF YELLOW FEVER VIRUS AMONG ACUTE FEBRILE PATIENTS ATTENDING SELECTED HEALTH FACILITIES IN BORENA DISTRICT, SOUTH-ERN ETHIOPIA. Ethiop Med J. 2020;58(1):58-62.
- Endale A, Michlmayr D, Abegaz WE, Asebe G, Larrick JW, Medhin G, et al. Community-based sero-prevalence of chikungunya and yellow fever in the South Omo Valley of Southern Ethiopia. PLoS Negl Trop Dis. 2020;14(9):e0008549.
- Lilay A, Asamene N, Bekele A, Mengesha M, Wendabeku M, Tareke I, et al. Reemergence of yellow fever in Ethiopia after 50 years, 2013: epidemiological and entomological investigations. BMC Infect Dis. 2017;17(1):343.
- Eshetu D, T A, TB W. Prevalence of Yellow fever virus infection and associated factors among acute febrile patients in Arbaminch districts, Southern Ethiopia. Preprint. Available from: https://doi.org/10.21203/rs.2. 23497/v1.
- Asebe G, Michlmayr D, Mamo G, Abegaz WE, Endale A, Medhin G, et al. Seroprevalence of Yellow fever, Chikungunya, and Zika virus at a community level in the Gambella Region, South West Ethiopia. PLoS One. 2021;16(7):e0253953.
- Mulchandani R, Massebo F, Bocho F, Jeffries CL, Walker T, Messenger LA. A community-level investigation following a yellow fever virus outbreak in South Omo Zone. South-West Ethiopia PeerJ. 2019;7:e6466.
- Eshetu D, Kifle T, Agaje BG, Hirigo AT. Seropositivity of West Nile Virus Among Acute Febrile Patients in Southern Ethiopia. Infect Drug Resist. 2020;13:1491–7.
- Nigussie E. Seroprevalence of West Nile Virus and Associated Factors in Borena District, Southern Ethiopia. Archives of Infect Diseases & Therapy. 2021;5(2):55-9.
- Ibrahim M, Schelling E, Zinsstag J, Hattendorf J, Andargie E, Tschopp R. Sero-prevalence of brucellosis, Q-fever and Rift Valley fever in humans and livestock in Somali Region, Ethiopia. PLoS Negl Trop Dis. 2021;15(1):e0008100.
- Geleta D, Tesfaye N, Ayigegn H, Waldetensai A, Gemechu F, H. A. Epidemiological Description of Chikungunya Virus Outbreak in Dire Dawa Administrative City, Eastern Ethiopia, 2019. . International Journal of Clinical and Experimental Medical Sciences. 2020;6(3):41-5.
- Ferede G, Tiruneh M, Abate E, Wondimeneh Y, Gadisa E, Howe R, et al. Evidence of chikungunya virus infection among febrile patients in northwest Ethiopia. Int J Infect Dis. 2020;104:183–8.
- Takele DB, Diriba S, Shikur M, Yoseph W, Abyot B, Y. A, et al. Factors Associated with Chikungunya Fever Outbreak in Ethiopia. Epidemiol Sci 2020;10(381):1-3.
- Assefa TY, Berhan E, Gemechu F, N. T. Risk Factors of Chikungunya Outbreak in Mareka District, Southern Ethiopia, 2019: Unmatched Case Control Study. . International Journal of Infectious Diseases and Therapy. 2020;5(3):64-9.
- Alayu M, Teshome T, Amare H, Kinde S, Belay D, Z A. Risk factors for Chikungunya outbreak in Kebridhar City, Somali Ethiopia, 2019. Unmatched Case-Control Study; 2020. Preprint. Available from: https://doi.org/10. 1101/2020.01.21.913673.
- Asebe G, Mamo G, Michlmayr D, Abegaz WE, Endale A, Medhin G, et al. Seroprevalence of Rift Valley Fever and West Nile Fever in Cattle in Gambella Region, South West Ethiopia. Vet Med (Auckl). 2020;11:119–30.
- 54. Endale A, Michlmayr D, Abegaz WE, Geda B, Asebe G, Medhin G, et al. Sero-prevalence of West Nile virus and Rift Valley fever virus infections among cattle under extensive production system in South Omo area, southern Ethiopia. Trop Anim Health Prod. 2021;53(1):92.
- Sibhat B, Ayelet G, Gebremedhin EZ, Skjerve E, Asmare K. Seroprevalence of Schmallenberg virus in dairy cattle in Ethiopia. Acta Trop. 2018;178:61–7.
- Abdullahi IN, Emeribe AU, Ghamba PE, Omosigho PO, Bello ZM, Oderinde BS, et al. Distribution pattern and prevalence of West Nile virus infection in Nigeria from 1950 to 2020: a systematic review. Epidemiol Health. 2020;42:e2020071.

- Lustig Y, Sofer D, Bucris ED, Mendelson E. Surveillance and Diagnosis of West Nile Virus in the Face of Flavivirus Cross-Reactivity. Front Microbiol. 2018;9:2421.
- Okechukwu C, Nasir I, Muhammad K, CN. C. Implications of Flaviviruses cross-reactivity and vaccination programs on their serodiagnosis. N Y Sci J. 2017;10(2):19-22.
- Nigussie E, Atlaw D, Negash G, Gezahegn H, Baressa G, Tasew A, et al. A dengue virus infection in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2024;24(1):297.
- 60. Gimenez-Richarte A, de Salazar MO, Arbona C, Gimenez-Richarte MP, Collado M, Fernandez PL, et al. Prevalence of Chikungunya, Dengue and Zika viruses in blood donors: a systematic literature review and meta-analysis. Blood Transfus. 2022;20(4):267–80.
- Li Z, Wang J, Cheng X, Hu H, Guo C, Huang J, et al. The worldwide seroprevalence of DENV, CHIKV and ZIKV infection: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2021;15(4):e0009337.
- 62. Serie C, Andral L, Poirier A, Lindrec A, Neri P. Studies on yellow fever in Ethiopia. 6. Epidemiologic study. . Bull World Health Organ 1968;38:879–84.
- 63. Oyono MG, Kenmoe S, Abanda NN, Takuissu GR, Ebogo-Belobo JT, Kenfack-Momo R, et al. Epidemiology of yellow fever virus in humans, arthropods, and non-human primates in sub-Saharan Africa: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2022;16(7):e0010610.
- 64. Saba Villarroel PM, Hamel R, Gumpangseth N, Yainoy S, Koomhin P, Misse D, et al. Global seroprevalence of Zika virus in asymptomatic individuals: A systematic review. PLoS Negl Trop Dis. 2024;18(4):e0011842.
- Liu R, Wang X, Ma Y, Wu J, Mao C, Yuan L, et al. Prevalence of Zika virus in blood donations: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):590.
- Metz MBC, Olufemi OT, Daly JM, Barba M. Systematic review and metaanalysis of seroprevalence studies of West Nile virus in equids in Europe between 2001 and 2018. Transbound Emerg Dis. 2021;68(4):1814–23.
- Ebogo-Belobo JT, Kenmoe S, Abanda NN, Bowo-Ngandji A, Mbaga DS, Magoudjou-Pekam JN, et al. Contemporary epidemiological data of Rift Valley fever virus in humans, mosquitoes and other animal species in Africa: A systematic review and meta-analysis. Vet Med Sci. 2023;9(5):2309–28.
- Peyre M, Chevalier V, Abdo-Salem S, Velthuis A, Antoine-Moussiaux N, Thiry E, et al. A Systematic Scoping Study of the Socio-Economic Impact of Rift Valley Fever: Research Gaps and Needs. Zoonoses Public Health. 2015;62(5):309–25.
- Wright D, Kortekaas J, Bowden TA, Warimwe GM. Rift Valley fever: biology and epidemiology. J Gen Virol. 2019;100(8):1187–99.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.